| Prev Close | 16.66 |
| Open | 16.68 |
| Day Low/High | 16.17 / 17.23 |
| 52 Wk Low/High | 5.65 / 20.50 |
| Volume | 94.93K |
| Avg Volume | 713.10K |
| Exchange | NASDAQ |
| Shares Outstanding | 23.40M |
| Market Cap | 33.92M |
| EPS | -1.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Ventrus Biosciences Files And Commences Mailing Of Definitive Proxy Materials For July 10th Annual Meeting
Stockholders Asked to Approve Issuance of Common Stock in Connection with Acquisition by Ventrus of Assembly Pharmaceuticals, Inc.
Big Swing Trade Ideas for Monday, June 2 With Huge Gain Potential
General Cable, Theravance and Ventrus Biosciences are our big swing trades for today. So how should investors buy and sell?
Ventrus Biosciences (VTUS) Stock Surges Today
Ventrus Biosciences (VTUS) surged Thursday despite a lack of significant news on the company in much the same way other biotech stocks Prana Biotechnology (PRAN) and DARA Biosciences (DARA) had risen earlier in the week.
Why Ventrus Biosciences (VTUS) Stock Plunged to a One-Year Low Today
Ventrus Biosciences (VTUS) plunged to a one-year low of 85 cents on Monday after the company agreed to merge with Assembly Pharmaceuticals in an all-stock transaction.
5 Stocks Poised for Breakouts
These stocks look ready to break out and trade higher from current levels.
3 Biotech Stocks Under $10 Making Big Moves
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ventrus Biosciences Completes Enrollment Of Second Pivotal Phase 3 Trial Of Diltiazem Cream (VEN 307) In Patients With Anal Fissure
Results Expected First Quarter 2014; NDA Filing Expected to Occur in Second Quarter 2014
Ventrus Biosciences Announces Positive Results From Clinical Dermal Safety And Pharmacokinetic Studies Of Diltiazem (VEN 307)
Results From Second Pivotal Phase 3 Trial in Anal Fissures Expected First Quarter 2014
VENTRUS BIOSCIENCES ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Ventrus Biosciences, Inc. Of Class Action Lawsuit And The Deadline Of July 8, 2013 To Seek A Lead Plaintiff Position
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ventrus Biosciences, Inc.
Ventrus Biosciences Announces Poster Presentation On The Quality Of Compounded Topical Diltiazem Hydrochloride Formulations For Anal Fissure At The American Pharmacists Association Meeting
Compounded Formulations From Retail Pharmacies Are Inaccurate in Respect to Potency Approximately 50% of the Time and Lack Content Uniformity Approximately 40% of the Time
5 Stocks Ready to Break Out
These stocks look poised to break out and trade higher from current levels.
Holzer Holzer & Fistel, LLC Announces Investigation Into Ventrus Biosciences, Inc.
Holzer Holzer & Fistel, LLC is investigating whether Ventrus Biosciences, Inc.
4 Stocks Under $10 Making Big Moves
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
The Five Dumbest Things on Wall Street This Week: June 29
Ventrus Gets Flushed; Amylin's Embarrassment; Chesapeake's Collusion; Falcone's Failure; Barclays Gets Busted.
The 5 Dumbest Things on Wall Street, June 29
Here is this week's roundup of the dumbest actions on Wall Street.
8 Stocks Rising on Unusual Volume
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
